Specialty:
Colon and Rectal Surgery
Clinical Interests:
Dr. Gantt specializes in the treatment of colon and rectal cancer, inflammatory bowel disease, anorectal disorders, and diverticular disease.
Publications
Turner PL, Oyetunji TA, Gantt GA, Chang DC, Cornwell EE, Fullum TM. Demographically Associated Variations in Outcomes After Bariatric Surgery. Am J Surg. 2011 Apr;201(4):475-80.
Gantt GA, Kalady MF. Molecular Markers For Targeted Neoadjuvant Rectal Cancer Therapy. Colorectal Cancer. 2013 Aug;2(4):321-331.
Mace AG, Gantt GA, Skacel M, Pai R, Hammel JP, Kalady MF. Statin Therapy is Associated with Improved Pathologic Response to Neoadjuvant Chemoradiation in Rectal Cancer. Dis Colon Rectum. 2013 Nov;56(11):1217-27.
Lotti F, Jarrar A, Pai RK, Masahiro H, Lathia J, Mace A, Gantt GA, Suhkdeo K, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN. Chemotherapy Induces Microenvironmental Remodeling to Instruct the Cellular Hierarchy in Colorectal Cancer. J Exp Med. 2013 Dec 16;210(13):2851-72.
Gantt GA, Chen Y, Sohal D, DeJulius K, Mace AG, Barnholtz-Sloan JS, Kalady MF. Gene Expression Signature Associated with Rectal Cancers With Poor Response to Chemoradiation. Colorectal Dis. 2014 Jan;16(1):57-66.
Gantt GA, Ashburn J, Kiran RP, Khorana A, Kalady MF. Laparoscopy Mitigates Adverse Oncological Effects of Delayed Adjuvant Chemotherapy for Colon Cancer. Surgical Endoscopy. 2015 Feb;29(2):493-9
Karagkounis G, Thai L, DeVecchio J, Gantt GA, Duraes L, Pai RK, Kalady MF. NPTX2 is Associated with Neoadjuvant Therapy Response in Rectal cancer. J Surg Res. 2016 May;202(1):112-7
Jarrar A, Lotti F, DeVecchio J, Ferrandon S, Gantt G, Mace A, Karagkounis G, Orloff M, Venere M, Hitmoi M, Lathia J, Rich JN, Kalady MF. PARP inhibition sensitizes colorectal cancer-initiating cells to chemotherapy. Stem Cells. 2019 Jan;37(1):42-53
